A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

Genmab's share price doubled over three months following positive results in cancer drug trials. The Danish biopharmaceutical company is increasing its ownership stake in medicines it develops. Genmab did not announce a specific date for the share movement or name the individual trials that drove the gains.

• CNBC — A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

Next story